iodoquinol (Rx)

Brand and Other Names:Yodoxin
  • Print

Dosing & Uses

AdultPediatricGeriatric

Dosage Forms & Strengths

tablets

  • 210mg
  • 650mg

Intestinal Amebiasis

650 mg PO PC q8hr for 20 days; not to exceed 2 g/day

Dosage Forms & Strengths

tablets

  • 210mg
  • 650mg

Intestinal Amebiasis

30-40 mg/kg/day divided PO PC q8hr PO for 20 days; not to exceed 1.95 g/day  

Not the drug of choice (may cause optic nerve damage); use only if other therapy is contraidicated or failed

Next:

Interactions

Interaction Checker

and iodoquinol

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 

            Contraindicated (0)

              Serious - Use Alternative (0)

                Monitor Closely (0)

                  Minor (3)

                  • cadexomer iodine

                    iodoquinol increases effects of cadexomer iodine by pharmacodynamic synergism. Minor/Significance Unknown.

                  • iodinated glycerol

                    iodoquinol increases effects of iodinated glycerol by pharmacodynamic synergism. Minor/Significance Unknown.

                  • iodine

                    iodoquinol increases effects of iodine by pharmacodynamic synergism. Minor/Significance Unknown.

                  Previous
                  Next:

                  Adverse Effects

                  Frequency Not Defined

                  Headache

                  Chills

                  Agitation

                  Diarrhea

                  Rash

                  Fever

                  Urticaria

                  Pruritus

                  Thyroid gland enlargement

                  Retrograde amnesia

                  Nausea

                  Vomiting

                  Peripheral neuropathy

                  Optic neuritis

                  Stomach pain

                  Weakness

                  Visual impairment

                  Optic atrophy

                  Abdominal cramps

                  Itching of rectal area

                  Previous
                  Next:

                  Warnings

                  Contraindications

                  Hypersensitivity to 8-hydroxyquinolones or iodoquinol

                  Iodine sensitivity

                  Pre-existing optic neuropathy

                  Hepatic damage

                  Cautions

                  Caution in thyroid disease

                  Interferes with thyroid tests for up to 6 months after discontiunation

                  Do not repeat course before 2-3 wk

                  Not effective in amebic hepatitis or liver abscess

                  Avoid long term thearpy (associated with optic neuritis and optic atrophy)

                  Previous
                  Next:

                  Pregnancy & Lactation

                  Pregnancy Category: C

                  Lactation: unknown

                  Pregnancy Categories

                  A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

                  B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

                  C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

                  D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

                  X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

                  NA: Information not available.

                  Previous
                  Next:

                  Pharmacology

                  Mechanism of Action

                  Acts primarily in intestinal lumen; mechanism unknown

                  Pharmacokinetics

                  Absorption: poor & erratic

                  Metabolism: Hepatic

                  Excretion: Primarily feces

                  Previous
                  Next:

                  Images

                  No images available for this drug.
                  Previous
                  Next:

                  Patient Handout

                  A Patient Handout is not currently available for this monograph.
                  Previous
                  Next:

                  Formulary

                  FormularyPatient Discounts

                  Adding plans allows you to compare formulary status to other drugs in the same class.

                  To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

                  Adding plans allows you to:

                  • View the formulary and any restrictions for each plan.
                  • Manage and view all your plans together – even plans in different states.
                  • Compare formulary status to other drugs in the same class.
                  • Access your plan list on any device – mobile or desktop.

                  The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

                  Tier Description
                  1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
                  2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
                  3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
                  4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
                  5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
                  6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
                  NC NOT COVERED – Drugs that are not covered by the plan.
                  Code Definition
                  PA Prior Authorization
                  Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
                  QL Quantity Limits
                  Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
                  ST Step Therapy
                  Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
                  OR Other Restrictions
                  Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
                  Additional Offers
                  Email to Patient

                  From:

                  To:

                  The recipient will receive more details and instructions to access this offer.

                  By clicking send, you acknowledge that you have permission to email the recipient with this information.

                  Email Forms to Patient

                  From:

                  To:

                  The recipient will receive more details and instructions to access this offer.

                  By clicking send, you acknowledge that you have permission to email the recipient with this information.

                  Previous
                  Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.